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and sensitivity.[4] Since the attenuation 
coefficient of X-ray is highly correlated 
with tissue density,[5] the current positive 
CT contrast agents (PCTCAs) exhibit high 
CT density value (CT-DV) and provide 
contrast enhancement in CT imaging.[6] 
However, CT with PCTCAs fails to accu-
rately detect diseases that have similar 
X-ray attenuations to surrounding tissues, 
such as osteosarcoma, the most common 
primary bone malignancy in skeletal 
system disease.[7] For example, enhanced 
CT scanning can barely distinguish osteo-
sarcoma from surrounding bones in high 
energy level images. This is because bones 
and PCTCAs of high-Z elements such as 
iodide, the lutecium-based upconversion 
nanoparticles,[8] can generate similar X-ray 
attenuations and then result in analogous 
high CT density between them. Conse-
quently, PCTCAs suffer from insufficient 
ability to distinguish osteosarcoma from 
bones. Rationally reducing the density 
of osteosarcoma can enhance the contrast between osteosar-
coma and bone, which is propitious to detect osteosarcoma 
sensitively.
How can we reduce the density of osteosarcoma? A phenom-
enon in clinical CT lung inspection demonstrates the lung has 
lower CT density than the surrounding tissues. Briefly, in CT 
The current positive computed tomography (CT) contrast agents (PCTCAs) 
including clinical iodides, present high CT density value (CT-DV). However, 
they are incapable for the accurate diagnosis of some diseases with 
high CT-DV, such as osteosarcoma. Because bones and PCTCAs around 
osteosarcoma generate similar X-ray attenuations. Here, an innovative 
strategy of negative CT contrast agents (NCTCAs) to reduce the CT-DV 
of osteosarcoma is proposed, contributing to accurate detection of 
osteosarcoma. Hollow mesoporous silica nanoparticles, loading ammonia 
borane molecules and further modified by polyethylene glycol, are synthesized 
as NCTCAs for the diagnosis of osteosarcoma. The nanocomposites can 
produce H2 in situ at osteosarcoma areas by responding to the acidic 
microenvironment of osteosarcoma, resulting in nearly 20 times reduction 
of CT density in osteosarcoma. This helps form large CT density contrast 
between bones and osteosarcoma, and successfully achieves accurate 
diagnosis of osteosarcoma. Meanwhile, The NCTCAs strategy greatly expands 
the scope of CT application, and provides profound implications for the 
precise clinical diagnosis, treatment, and prognosis of diseases.
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As a prolific diagnostic imaging tool in clinic, X-ray computed 
tomography (CT) is of great significance for detecting cen-
tral nervous system disease,[1] cardiovascular disease,[2] and 
tumors[3] due to its high time resolution, density resolution, 
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images, lung cavity with low CT density shows up as a dark 
region,[9] while ribs of high CT density beside the lung present 
distinctly highlight signals. This is because the lung cavity full 
of gas has less X-ray attenuation, on the contrary, the ribs pos-
sess higher X-ray attenuation. This phenomenon inspires us 
that we can take advantage of gas to reduce CT density of osteo-
sarcoma, further resulting in striking definition between osteo-
sarcoma and bones, and finally achieve accurate osteosarcoma 
diagnosis.
Herein, we proposed a novel strategy of negative CT con-
trast agents (NCTCAs) for the precise diagnosis of solid tumors 
without a cavity, such as osteosarcoma. NCTCAs with lower CT 
density were capable of reducing the CT density value of target 
lesion areas, which made lesion areas exhibit dark signals in CT 
images, and further achieving accurate diagnosis. We designed 
a negative CT contrast agent HMSN@AB@PEG that produced 
gas in situ at the osteosarcoma site,[10] and sharply reduced the 
CT density in tumors. A large density difference contrast formed 
between osteosarcoma and bone, and further resulted in accu-
rate diagnosis of osteosarcoma (Scheme 1). Briefly, ammonia 
borane (AB) molecules, as H2 storage mediums, were utilized 
as H2 donors and efficiently loaded in hollow mesoporous silica 
nanoparticles (HMSN) by electrostatic adsorption and hydrogen 
bond interaction. Then, the nanocomposites could respond 
to the acid microenvironment of osteosarcoma and release 
H2. That was the reaction of NH3BH3 + H+ + 3H2O→NH4 + 
B(OH)3 + 3H2 (Figure 1). The product H2 could reduce the CT 
density of tumor area, resulting in remarkable contrast between 
osteosarcoma and bones, through which was conceivable to 
detect osteosarcoma precisely. Moreover, this strategy made it 
possible to detect solid tumors without a cavity using NCTCAs. 
The outcome of this study implied that the application scope 
of CT could be greatly expanded, providing profound implica-
tions for accurate clinical diagnosis, treatment, and prognosis 
of tumors and other diseases.
2. Results and Discussions
2.1. Synthesis and Characterization  
of HMSN@AB@PEG
Monodispersed HMSN nanoparticles were synthesized 
according to a classical selective etching strategy with some 
modifications.[11] Briefly, dense solid SiO2 nanoparticles 
were first fabricated through a typical Stöber method 
(Figures S1A,B and S2A, Supporting Information). Mesoporous 
silica shells were then coated on the surface of solid SiO2 nano-
particles (Figures S1C,D and S2B, Supporting Information). Sub-
sequently, the nanoparticles were selectively etched in Na2CO3 
solution, and further extracted in NH4Cl solution to form the 
final HMSN nanoparticles. The obtained HMSN nanoparticles 
presented uniformly spherical feature (Figure 2A) with good 
hydrodynamic size distribution centered at 313.3 nm (Figure S3A, 
Supporting Information), which indicated that HMSN owned 
high dispersity without apparent aggregation. After loading 
with AB and PEG molecules (Figure 2D), the morphology of 
HMSN@AB@PEG still kept intact and the hydrodynamic size 
distribution centered at 339.5 nm (Figure S3B, 
Supporting Information). Meanwhile, the 
zeta potential of HMSN turned from 
−18.1 to −7.26 mV (HMSN@AB) after loading 
AB molecules (Figure S4, Supporting Informa-
tion). Besides, scanning electron microscopy 
(SEM) images also verified the spherical and 
monodispersed morphology of as-synthesized 
HMSN and HMSN@AB@PEG (Figure 2B,E).
AB as one of popular hydrogen storage 
materials[12] has long been favored among 
hydrogen energy development.[13] Herein, 
we utilized AB molecules as H2 gas donors 
to construct a kind of CT gas contrast agent 
to monitor osteosarcoma. Fourier transform 
infrared (FTIR) spectra exhibited AB mole-
cules were successfully encapsulated into 
HMSN, as indicated by the overlap of charac-
teristic peaks of HMSN and AB (Figure 2C). 
Subsequently, the N2 adsorption–desorption 
tests showed that HMSN had a larger spe-
cific surface area of 801.14 m2 g−1 (Figure 2F) 
and two pore sizes of 2.78 and 3.87 nm 
(Figure S5, Supporting Information). The dif-
ferent pore sizes may be attributed to alkaline 
Na2CO3 solution etching. After loading AB 
molecules, the specific surface area of HMSN 
dramatically decreased and the mesoporous 
properties disappeared, indicating the 
successful loading of AB. As shown in 
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Scheme 1. Schematic diagram of negative CT contrast agents for the accurate diagnosis of 
osteosarcoma, the area of dashed line is osteosarcoma. Apparently, negative CT contrast 
agents HMSN@AB@PEG could produce H2 to decrease the CT density value in the osteosar-
coma area, further distinguishing osteosarcoma from bone, while the clinical CT contrast agent 
Iobitridol indistinguishes osteosarcoma from bone because of the similar X-ray attenuations 
generated by bones and Iobitridol around osteosarcoma, both of which reveal high CT density.
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Figure S6 (Supporting Information), the thermogravimetric 
analysis (TGA) data presented about 20.7 wt% mass loss, which 
further demonstrated AB molecules were successfully married 
to HMSN nanoparticles.
2.2. H2 Release and Negative CT Contrast Performance  
in Aqueous Solutions of Different pH
AB molecules could release H2 by responding to acid, followed 
by the reaction of NH3BH3 + H+ + 3H2O→NH4 + B(OH)3 + 3H2. 
So gas chromatography was utilized for qualitative and 
quantitative analysis of H2. At first step, a standard curve of 
different volume of H2 was drawn (Figure S7, Supporting Infor-
mation). HMSN@AB@PEG nanoparticles were then dispersed 
in phosphate buffered saline (PBS) (pH 6.3) in a sealed container 
to react for 4 h. Subsequently, 1 mL microsyringe was used to 
assimilate the upper gas in the container and transferred the 
gas into the vaporizer immediately. Eventually, the H2 release 
volume from HMSN@AB@PEG was calculated as 2.4347 mL 
(Figure 3A), and the dynamic curve of H2 release was obtained 
as well (Figure 3B). According to the equation pV = nRT, the 
H2 mass was calculated to be about 0.196 mg. The H2 release 
process from free AB molecules and HMSN@AB@PEG in dif-
ferent pH (5.3, 6.3, 7.4) PBS was also recorded. Obviously, free 
AB molecules quickly turned into H2 in acidic conditions, in 
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Figure 1. Diagram of HMSN@AB@PEG synthesis and H2 release mechanism.
Figure 2. A,B) TEM and SEM images of HMSN; C) FTIR of AB, HMSN, HMSN@AB, and HMSN@AB@PEG; D,E) TEM and SEM images of HMSN@
AB@PEG; F) N2 adsorption and desorption isothermal curves of HMSN and HMSN@AB.
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addition, the higher acidity could speed the H2 release process 
(Figure S8 and Video S1, Supporting Information). As a con-
trast, the similar phenomena was observed from HMSN@AB@
PEG nanoparticles responding to acid (Figure S9 and Video S2, 
Supporting Information), which demonstrated HMSN@AB@
PEG had the potential to release H2 as negative CT contrast 
agents in the acidic microenvironment of tumors. However, in 
PBS (pH 7.4), both of free AB molecules and HMSN@AB@
PEG nanoparticles revealed no apparent AB decomposition/H2 
release, indicating that HMSN@AB@PEG nanoparticles could 
not produce H2 in normal tissue environment.
We further investigated the CT contrast performance of 
HMSN@AB@PEG based on the above. First, H2 bubbles 
released in acidic solutions (pH 5.3, 6.3) instead of neutral pH 
solution (pH 7.4) (Figure 3C). Aqueous solutions of HMSN@
AB@PEG in different pH (5.3, 6.3, 7.4) were then imaged 
using a CT scanner. Evidently, in acidic solutions, the region of 
interest (ROI) gradually decreased in CT images, on account of 
which H2 bubbles released to result in lower CT density. How-
ever, that of neutral pH solution changed little. Meanwhile, 
the normalized CT value of corresponding solutions relative 
to water was also calculated and summarized. The outcome 
implied higher acidity made more remarkable signals 
(Figure 3D,E). Even in a slight acid environment (pH 6.3) anal-
ogous to the acid microenvironment of tumors,[14] the notable 
decrease of CT density value was also observed, demonstrating 
remarkable CT contrast performance of HMSN@AB@PEG. 
Moreover, the CT contrast performance of free AB molecules 
was also investigated, which showed analogous results with 
HMSN@AB@PEG (Figure S10, Supporting Information).
2.3. The Cellular Biocompatibility of HMSN@AB@PEG
To study the biocompatibility of HMSN@AB@PEG nanopar-
ticles, 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide (MTT) assay was implemented to evaluate the cel-
lular cytotoxicity of HMSN@AB@PEG nanoparticles acting on 
osteosarcoma MG63 cells. There was no obvious cytotoxicity 
of HMSN@AB@PEG against the cells during a wide concen-
tration range (0–100 ppm) (Figure S11, Supporting Informa-
tion). Afterward, the phagocytosis of HMSN@AB@PEG 
nanoparticles by the cells was monitored by laser confocal fluo-
rescence imaging (Figure S12A–C, Supporting Information). 
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Figure 3. A,B) Gas chromatography of H2 release and dynamic curve of H2 release; C) H2 release images of HMSN@AB@PEG in different pH (5.3, 6.3, 
7.4) after half hour, and the sites of the arrows are H2 bubbles; D) CT images of HMSN@AB@PEG in different pH (5.3, 6.3, 7.4). Obviously, CT value 
decreased in consequence of H2 release and the area of white line was the region of interest (ROI). E) Normalized CT value relative to water of the 
corresponding solutions, calculated by the average HU value of eight slices.
www.advancedsciencenews.com
1901214 (5 of 8) © 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedscience.com
After incubated with HMSN@AB@PEG nanoparticles with 
fluorescein isothiocyanate (FITC) at 310 K for 4 h, the cells 
presented brightly green fluorescence, which demonstrated the 
cells could swallow the nanoparticles successfully. Moreover, 
the quantization line of FITC fluorescence intensity is shown 
in Figure S12D (Supporting Information), and the 3D video of 
FITC fluorescence intensity was also recorded, which exhibited 
higher FITC fluorescence intensity with high signal-to-noise 
ratio (Video S3, Supporting Information).
2.4. Negative CT Contrast Performance of HMSN@AB@PEG 
In Vivo
We next validated the CT imaging performance of HMSN@
AB@PEG nanoparticles in vivo. First, we evaluated the osteosar-
coma diagnosis efficiency by intratumor and intravenous injec-
tion of clinical CT contrast agent Iobitridol as PCTCAs. After 
intratumor injection of Iobitridol (350 000 ppm of I, 500 µL), 
the CT density of osteosarcoma area rapidly rose, presenting 
highlight signals in CT images (Figure S13, Supporting Infor-
mation). However, we could not clearly distinguish the bone 
morphology from osteosarcoma. While intravenous injection of 
HMSN@AB@PEG (Figure S14, Supporting Information), we 
observed the similar results that we could not differentiate bone 
from tumor through both of gray and pseudo-color images 
(transvers). We then evaluated the negative CT contrast perfor-
mance of AB molecules in vivo (Figure S15, Supporting Infor-
mation). Apparently, intratumor injection of AB molecules was 
capable of negative CT contrast performance soon. With the 
increase of hydrogen, CT density decreased gradually, which 
demonstrated AB molecules after intratumor injection enabled 
to produce H2 by responding to the tumor acidic microenviron-
ment. In contrast, after intravenous of AB molecules, the CT 
density of tumor almost unchanged, which was attributed to 
the rapid metabolism of AB molecules in vivo and further led 
to ineffectively enrich in tumor.
After injection of HMSN@AB@PEG nanoparticles 
(30 000 ppm, 500 µL) into tumor, the CT density value of 
osteosarcoma obviously decreased along with the genera-
tion of H2 (Figure 4A). From gray and pseudo-color images 
(transvers), we could accurately diagnose osteosarcoma no 
interference with bone of high CT density. The corresponding 
gray (Figure S16, Supporting Information) and pseudo-color 
(Figure S17, Supporting Information) images (coronal) also 
indicated that a remarkable contrast emerged between bone 
with high CT density and osteosarcoma with low CT density. 
Furthermore, we measured the change of CT density value 
in rectangular ROI at two time points (Pre and 120 min) 
(Figure S18, Supporting Information). The CT density value of 
osteosarcoma significantly decreased, but the CT density value 
of normal tissues hardly changed. And the reduction extent of 
CT density was as high as 20 times. Besides, gray CT images 
(240 min) of different slices in the osteosarcoma were recorded 
as well (Video S4, Supporting Information). Finally, to further 
verify that gas did localize in the tumor area, digital image 
(Figure S19A, Supporting Information) and corresponding 
3D reconstruction map (Figure 4B) of osteosarcoma-bearing 
rat were supplemented. HMSN@AB@PEG was intratumorly 
injected into another osteosarcoma-bearing rat 240 min later, 
CT imaging and magnetic resonance imaging (MRI) were con-
ducted simultaneously. Obviously, CT density of the tumor 
decreased significantly (Figure S19B, Supporting Information). 
From the images of MRI (Figure S19C,D, Supporting Informa-
tion), we could clearly find the location of osteosarcoma and 
there was much black phantom in the tumor, of which was 
caused by the produced H2 on account.
Next, we also evaluated the diagnosis performance of oste-
osarcoma after the intravenous injection of HMSN@AB@
PEG. Analogously, as shown in Figure 4C,D, the reduced CT 
density value was clearly observed in tumor region compared 
with normal tissues after 2 h post-injection. From the pseudo-
color images (transvers), we could easily discover the position 
of low CT density around the right leg of rat, indicating suc-
cessful detection of osteosarcoma. Compared with AB mole-
cules, this also demonstrated the important role of HMSN. 
The corresponding gray (Figure S20, Supporting Information) 
and pseudo-color (Figure S21, Supporting Information) images 
(coronal) also clearly suggested that HMSN@AB@PEG as a 
negative CT contrast agent presented effective diagnosis of 
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Figure 4. CT imaging of osteosarcoma-bearing rats by intratumor and 
intravenous injection of HMSN@AB@PEG nanoparticles (at several 
time points). A,C) The intratumor and intravenous transvers gray images 
and corresponding pseudo-color images were obtained. B,D) The corre-
sponding 3D reconstruction maps of rat were obtained, intratumor and 
intravenous. The region of dashed line was the area of osteosarcoma, 
and the region of arrows was the low CT density area of H2 release. The 
two rectangle ROI in gray images (one was inside tumor, the other was 
in normal tissues) were selected to calculate the variation of CT density 
value between two time points (Pre and 120 min). FOV: 198 × 198 mm, 
W/L: 300/40.
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osteosarcoma. Furthermore, we calculated the change of CT 
density value in rectangular ROI at two time points (Pre and 
120 min) before and after intravenous injection of HMSN@
AB@PEG (Figure S22, Supporting Information). Similar to 
the intratumor injection, the CT density value of osteosarcoma 
reduced, while it hardly changed around normal tissues. The 
reduction extent of CT density was still about two times. From 
the above outcomes, we knew the strategy of NCTCAs for diag-
nosis of osteosarcoma was practicable.
2.5. The Biocompatibility In Vivo
Encouraged by the excellent negative CT contrast performance 
of HMSN@AB@PEG nanoparticles, the toxicity in vivo should 
be further studied. 100 µL of HMSN@AB@PEG solution 
(30 000 ppm) or PBS (as control) was intravenously injected 
into ICR mice to observe the variation of weight and physio-
logical actions for 3 and 30 d. The bodyweight kept almost the 
same between both the groups (Figure S23, Supporting Infor-
mation), at the same time, the results of serum biochemistry 
and hematology also exhibited little difference (Figure S24, 
Supporting Information). The hematoxylin and eosin (H&E) 
staining analysis of organs including heart, liver, spleen, lung, 
and kidney also showed similar morphologies between experi-
ment groups and control groups (Figure S25, Supporting Infor-
mation), further demonstrating the excellent biocompatibility 
and negligible side effects of HMSN@AB@PEG, which was 
suitable as negative CT contrast agent. Finally, we investigated 
the distribution of HMSN@AB@PEG in each organ. After 4 h 
intravenous injection of HMSN@AB@PEG, we found most of 
HMSN@AB@PEG were distributed in the liver and spleen, a 
few were in tumor (Figure S26, Supporting Information). And 
the H&E staining image of tumor was supplemented to verify 
the existence of tumor (Figure S27, Supporting Information).
3. Conclusion
In summary, we achieved successful detection of osteosarcoma 
through NCTCAs strategy. HMSN@AB@PEG nanoprobes as 
NCTCAs could specifically respond to the acidic microenvi-
ronment of tumors, and finally achieve sensitive detection of 
osteosarcoma. HMSN@AB@PEG nanoprobes had excellent 
biocompatibility and low toxicity. In vitro and in vivo experi-
ments showed that HMSN@AB@PEG could rapidly generate 
H2 gas in the tumor area and then significantly reduce the CT 
density value in tumor region. The reduction extent of CT den-
sity was nearly as high as 20 times after intratumor injection of 
HMSN@AB@PEG. This helped form a sharp contrast between 
bones and osteosarcoma, and further realize accurate diagnosis 
of osteosarcoma. The strategy of NCTCAs that included gas or 
materials of low CT density was able to realize the precise diag-
nosis of diseases with high CT density, such as osteosarcoma, 
meanwhile, to provide a new idea for the detection of solid 
tumors without a cavity. Altogether, the strategy of NCTCAs 
could overwhelmingly promote the scope of CT application and 
provide profound implications for the diagnosis, treatment, and 
prognosis of tumors and other diseases in clinic.
4. Experimental Section
Materials: Cetyltrimethylammonium chloride (CTAC), triethanolamine 
(TEA), and tetraethyl orthosilicate (TEOS) were purchased from Sigma-
Aldrich; phosphate buffer solution was prepared by Na2HPO4, KH2PO4, 
hydrochloric acid, and deionized water. Na2HPO4, KH2PO4, AB, and 
Na2CO3 were acquired from Tansoole. Amino-polyethylene glycol 
with molecular weight 2000 was purchased from Shanghai ToYong 
Biotechnology Co., Ltd. The NH4Cl, hydrochloric acid, and ethanol were 
purchased from Sinopharm Chemical Reagent Co., Ltd. All reagents 
were analytical without any purification unless otherwise specified.
Characteristics: Transmission electron microscopy (TEM) morphology 
was recorded on a JEOL JEM-2100 at 200 kV (JEOL Ltd., Japan). 
SEM images were carried on a Hitachi S-48000 scanning electron 
microscope. Dynamic light scattering (DLS) tests were conducted on a 
Malvern ZetasizerNano ZS analyzer. FTIR spectra were collected on a 
TENSOR II FT-IR spectrophotometer (Bruker Corporation) by KBr. The 
concentration of materials and elements were quantified by an inductive 
coupled plasma (ICP) emission spectrometer (Agilent Technologies 
5100 ICP-OES). Gas chromatography was measured by a GC2060 gas 
chromatography system. The videos of gas releasing were acquired by 
an Apple Phone 7+. The CT measurements were obtained by a clinical 
CT instrument (GE discovery CT750 HD).
Preparation of Hollow Mesoporous SiO2 Particles: First of all, 
monodispersed solid SiO2 nanoparticles were prepared referring to 
the typical Stöber methods.[11] Briefly, ultrapure water (10 mL), alcohol 
(74 mL), and ammonia solution (33% wt) (3.14 mL) were mixed 
homogeneously and stirred for 5 min in a 303 K water bath. Then 6 mL 
of TEOS was followed adding into the solution. After the above mixture 
was stirred for 1 h, solid SiO2 nanoparticles were obtained and washed 
with ethanol three times, then dispersed again in 60 mL deionized 
water. Second, 2 g CTAC and 0.4 g TEA were together added into 90 mL 
deionized water and stirred for 1.5 h to create a homogeneous phase. 
Then SiO2 (30 mL) aqueous solution was added and stirred for another 
1.5 h. TEOS (1.8 mL) was added into the above solution dropwise and 
the mixture continued to be stirred for 1 h in a 353 K water bath. The 
resulting SiO2@SiO2 particles were centrifuged and washed three times 
by ethanol, and dispersed again in 30 mL of deionized water. Afterward, 
18 mmol of Na2CO3 was added into the above solution and the system 
was stirred for 1 h at 353 K. The obtained nanoparticles were centrifuged 
and washed three times by deionized water. Eventually, CTAC was 
extracted by a rapid ion exchange method. Briefly, the above particles 
were dispersed in ethanol (60 mL) containing 3 g of NH4Cl and the 
system was further stirred at 333 K for 4 h.[15] The resulting nanoparticles 
(HMSN) were centrifuged and washed three times by ethanol, and then 
dispersed in ethanol (80 mL).
Preparation of HMSN@AB@PEG: First of all, AB molecules (150 mg) 
were dissolved in HMSN aqueous solution (1 mL, 30 mg mL−1) 
completely, and then the system was stirred for 24 h at room temperature. 
AB molecules were trapped into the HMSN cavities and mesoporous 
channels through electrostatic adsorption and hydrogen bonding 
interaction. Afterward, HMSN@AB nanoparticles were collected by 
centrifugation and washed by deionized water. The resulting nanoparticles 
were dried via vacuum freeze-drying for further use.
Then 100 mg of HMSN@AB nanoparticles were redispersed in 
10 mL of ultrapure water. NH2-PEG-2000 molecules (500 mg) were 
added into the solution, and the system was continuously stirring for 
another 24 h. At last, HMSN@AB@PEG nanoparticles were collected 
by centrifugation, washed by deionized water, and dried via vacuum 
freeze-drying.
Cells Toxicity Assessment of HMSN@AB@PEG: MG63 osteosarcoma 
cells were seeded in Dulbecco modified Eagle’s medium (DMEM) 
with 9% fetal bovine serum (FBS) and 1% penicillin/streptomycin at 
310 K for 24 h and with 5% CO2 with a density of 104/well.[16] Different 
concentrations (100, 50, 25, 12.5, 6.25 ppm) of HMSN@AB@PEG 
particles were added to the wells and coincubated for another 24 h. 
Subsequently, cell viability was tested by a typical MTT assay. Typically, 
100 µL of MTT (0.6 mg mL−1) was added in each well and coincubated 
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for 4 h, and the medium was then replaced by 100 µL of DMSO into 
per well. Several minutes later, the absorbance of the medium was 
monitored by a microplate reader (Bio-TekELx800) at the 490 nm 
wavelength.
The Confocal Fluorescence Images to Observe the Cellular Uptake of 
HMSN@AB@PEG: To monitor the cellular uptake of HMSN@AB@
PEG, HMSN@AB@PEG was modified by FITC. Briefly, FITC (1 mg) was 
dissolved in 10 mg mL−1 of HMSN@AB@PEG aqueous solution, and 
the system was stirred for 24 h. The final nanoparticles were centrifuged 
and washed three times by deionized water, and then redispersed 
in DMEM with 2% FBS as follows. 5 × 103 MG63 osteosarcoma cells 
were cultured with DMEM containing 2% FBS in a coverglass dish at 
310 K for 24 h and with 5% CO2. Subsequently, 100 ppm of HMSN-FITC 
were added into the media and incubated for 4 h, and then the media 
was washed three times with physiological saline solution (PBS) for 
removing the free HMSN-FITC. Finally, PBS (1 mL) was added into the 
media and the confocal fluorescence imaging experiments were carried 
out by using Nikon Confocal Microscope A1R+-980 (Nikon Corporate, 
Japan).
In Vivo Toxicity Evaluation of HMSN@AB@PEG: Healthy Institute 
of Cancer Research (ICR) mice (≈35 g) were purchased and divided 
into three groups. 100 µL of HMSN@AB@PEG (30 000 ppm) was 
intravenously injected into ICR mice of experiment groups. As a contrast, 
100 µL of PBS was injected into the control group. The experimental 
groups were sacrificed to study the short and long-term toxicity of 
HMSN@AB@PEG at 3 and 30 d. The dissected tissues comprising 
heart, liver, spleen, lung, and kidney were H&E stained for histological 
analysis. Besides, the blood of mice was extracted for the toxicity 
investigation. All animal experiments were performed according to the 
guidelines of the Regional Ethics Committee for Animal Experiments, 
and the care regulations authorized by the Administrative Committee 
of Laboratory Animals of East China Normal University (accreditation 
number: m+ R20190701).
Percentage Distribution of Si Element in Various Organs and Blood: 
100 µL of HMSN@AB@PEG (30 000 ppm) was intravenously injected 
into three ICR mice. After 4 h, the mice were sacrificed to obtain the 
dissected tissues comprising heart, liver, spleen, lung, kidney, and 
tumor. The dissected tissues were further dispersed in nitrohydrochloric 
acid. Two weeks later, the Si element was quantified according to ICP.
Investigation of AB Loading Capacity of HMSN: The AB loading 
capacity of HMSN was evaluated by TGA. First, almost 5 mg of HMSN@
AB nanoparticles were dried via vacuum freeze-drying overnight. TG test 
was implemented through temperature procedure from 298 to 1073 K, 
10 K min−1. Finally, the TG curve was obtained, by which the AB loading 
capacity of HMSN was calculated to be 20.7%.
Checkout of H2 Release from HMSN@AB@PEG Nanoparticles in pH 
6.3 PBS: First of all, gas chromatography was utilized to draw a standard 
curve of different volume of H2. Subsequently, 2.5 mg of HMSN@AB@
PEG nanoparticles were dispersed in PBS (pH 6.3) and reacted for 4 h. 
Then one injection syringe was used to suck up the above gas (1 mL) in 
the container and injected into the vaporizer with carrier Ar gas. Eventually, 
H2 release volume from HMSN@AB@PEG was calculated as 2.4347 mL. 
According to the equation pV = nRT, H2 mass was about 0.196 mg.
CT Intensity of Different Solutions: All CT tests were performed on a 
clinical CT machine GE discovery CT750 HD, GE Healthcare in Huashan 
Hospital Affiliated to Fudan University. Several aqueous solutions 
containing HMSN@AB@PEG in different pH were investigated. And the 
test condition were abdomen, slice thick speed 0.625 mm. All aqueous 
solutions were put in 2 mL tube, and the final signal intensity was the 
average CT value of all slices.
Construction of MG63 Tumor-Bearing SD Rat Model: The SD rats 
of about 300 g were purchased and raised at least two weeks before 
experiments. Then 200 µL of DMEM containing MG63 cells (108) was 
injected near fibula and tibia. One week later, another same injection 
was performed to make sure the model was successful.
CT Imaging In Vivo: CT images in vivo were performed with 
conventional CT scanning mode. CT images of MG63 tumor-bearing 
SD rats were conducted in different time periods after the intratumor 
and intravenous injection of 500 µL HMSN@AB@PEG solution 
(30 000 ppm). The tube voltage was 120 kVp, slice thickness was 
0.625 mm.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
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